CTOs on the Move


 
SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.spalab.com
  • 1125 Linda Vista Dr Ste 106
    San Marcos, CA USA 92078
  • Phone: 888.633.0012

Executives

Name Title Contact Details

Similar Companies

Specialty Operations Solutions

Specialty Operations Solutions, Inc. is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flowr Corporation

The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.

Amedra Pharmaceuticals

Amedra Pharmaceuticals is a Middlesex, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kleo

Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.